Page 90 - controlled drug delievery

Examples of marketed Liposomes

• Cont. Caelyx/Doxil®:

– Recommended dose 20-50 mg/m2 every 4 weeks as
compared to 60-90 mg/m2 every 3 weeks in case of non
liposomal formulation (Adriamycin®)

– Vd of Doxrubicin: 2.5 L/m2 (Doxil) & 24-69 L/m2 (Adriamycin)

– Cardiotoxicity: Insignificant in Doxil up to 1500 mg/m2
commulative dose versus high risk of cardiac toxicity with
conventional injections at 400 mg/m2 commulative dose

– Repeated administration is limited by palmar-plantar
erythrodysaesthesia (ulceration & blisters of the palms &
soles due to dug accumulation in the skin of these areas